Scott Akamine - 05 Dec 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role
Chief Legal Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
05 Dec 2023
Net transactions value
-$445,725
Form type
4
Filing time
07 Dec 2023, 19:45:05 UTC
Previous filing
08 Feb 2023
Next filing
21 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $98,775 +7,500 +1462% $13.17 8,013 05 Dec 2023 Direct F1, F2
transaction CERE Common Stock Sale $262,500 -7,500 -94% $35.00 513 05 Dec 2023 Direct F1
transaction CERE Common Stock Options Exercise $131,700 +10,000 +1949% $13.17 10,513 07 Dec 2023 Direct F1
transaction CERE Common Stock Sale $413,700 -10,000 -95% $41.37 513 07 Dec 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -7,500 -2.8% $0.000000 264,262 05 Dec 2023 Common Stock 7,500 $13.17 Direct F1, F3
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -10,000 -3.8% $0.000000 254,262 07 Dec 2023 Common Stock 10,000 $13.17 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person.
F2 Includes 513 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023.
F3 25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.